Chi siamo

Chi siamo

Redazione

MICI360 è il sito web, nato da un’idea di Janssen, dedicato all’approfondimento, all’informazione e alla conoscenza delle Malattie Infiammatorie Croniche Intestinali. L’obiettivo del sito è fornire informazioni e creare consapevolezza su temi inerenti la malattia, i sintomi, le possibili cause, la prevenzione e la cura mettendo a disposizione approfondimenti, news e video interviste ai medici.

Chi sono i nostri esperti? Scopri il Board Scientifico.

Dott.ssa Emma Calabrese, laureata nel 1999, in Medicina e Chirurgia, presso la Sapienza Università di Roma, ottiene la specializzazione in Gastroenterologia ed Endoscopia Digestiva, nel 2003 sempre presso la “Sapienza”. Dopo il Dottorato di Ricerca in Fisiopatologia Sperimentale indirizzo Infiammazione Mucosale (anno 2003-2006) presso Università degli Studi di Roma “Tor Vergata”, si specializza ulteriormente tra il 2009 e il 2010 presso la University of Chicago, Illinois, United States sotto la guida del Prof. Hanauer (Chief of Department of Gastroenterology, Hepatology and Nutrition, University of Chicago, Illinois, USA). Abilitata alla professione di Medico Chirurgo nel maggio del 2000, attualmente ricopre la carica di Ricercatore presso la Cattedra di Gastroenterologia, Dipartimento di Medicina dei Sistemi, Università degli Studi di Roma “Tor Vergata” ed afferente alla UOC di Gastroenterologia, Dipartimento di Medicina, Policlinico Universitario Tor Vergata, Roma (Prof G. Monteleone).

Dott. Davide Giuseppe Ribaldone laureato nel 2011, in Medicina e Chirurgia, presso l’università degli studi di Torino, ottiene la specializzazione in Gastroenterologia ed Endoscopia Digestiva, nel 2017. Vanta numerose pubblicazioni in collaborazione con centri di eccellenza italiani ed europei, presso la Clinica ambulatoriale dell’azienda ospedaliera città della salute di Torino, centro di eccellenza per le malattie infiammatorie intestinali, Endoscopia digestiva (gastroscopia diagnostica e operativa e colonscopia).

Norina Wendy Di Blasio, laureata in Filosofia della scienza, presso la Sapienza Università di Roma, nel 2001. Si occupa da anni di comunicazione e divulgazione scientifica. Segue la progettazione e il coordinamento redazionale per la realizzazione di prodotti editoriali e per il web a carattere medico-scientifico, sia rivolti al paziente sia al medico di base e specialista.Collabora attualmente con i seguenti siti sia in qualità di autrice sia di photo e scientific editor: Il Pensiero Scientifico Editore, Saluteinternazionale.info, Careonline.it – Care. Costi della Assistenza e Risorse Economiche, Società Italiana dell’Ipertensione Arteriosa (SIIA), Federazione delle Associazioni Emofilici ONLUS (FedEmo), Studio Folic Trial.Ha curato la progettazione e la realizzazione corsi E-learning rivolti al personale medico-sanitario dell’Azienda Autonoma di Bolzano.Per la Federazione Italiana contro l’Epilessia (LICE) ha curato l’ideazione e la realizzazione del progetto “Facciamo luce sull’epilessia a scuola”, con l’obiettivo di diffondere una maggiore conoscenza, sensibilizzazione e consapevolezza di questa malattia a scuola e per verificare il grado di consapevolezza degli insegnanti su come gestire la presenza di un bambino epilettico in classe.È coautrice del testo “Diciamolo chiaramente. Testi, immagini, poster e powerpoint per una comunicazione medico-scientifica efficace”.

Hai ancora dei dubbi?


Bibliografia

  1. Gomollón F, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017 Jan;11(1):3-25
  2. Magro F, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017 June, 11, 6(1):649–670
  3. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429.
  4. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–217.
  5. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. J Am Med Assoc. 1932;99:1323–1329.
  6. Mulder DJ, Noble AJ, Justinich CJ, et al. A tale of two diseases: the history of inflammatory bowel disease. J Crohns Colitis. 2014;8:341-348.
  7. Adams EW. Founders of modern medicine: Giovanni Battista Morgagni (1682–1771). Med Libr Hist J. 1903;1:270–277.
  8. www.amiciitalia.eu
  9. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–217.
  10. Halme L, Paavola-Sakki P, Turunen U, et al. Family and twin studies in inflammatory bowel disease. World J Gastroenterol. 2006;12:3668.
  11. Vermeire S. NOD2/CARD15: relevance in clinical practice. Best Pract Res Clin Gastroenterol. 2004;18:569–575.
  12. Mahid SS, Minor KS, Soto RE, et al. Smoking and Inflammatory Bowel Disease: a Meta-analysis. Mayo Clin Proc. 2006;81:1462–1471.
  13. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489–1499.
  14. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30:699–706.
  15. Gajendran M, Loganathan P, Catinella AP, et al. A comprehensive review and update on Crohn's disease. Dis Mon. 2017 Aug 18. [Epub ahead of print]
  16. Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670.
  17. Lönnfors S, Vermeire S, Greco M, et al. IBD and health-related quality of life: discovering the true impact. J Crohns Colitis. 2014;8:1281-1286.
  18. Kim YS, Jung SA, Lee KM, et al. Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2017;15:338-344.
  19. Cross RK Jr. Telemanagement for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2014;10:255–257.
  20. Redmond C, Cowin C, Parker T. The experience of faecal leakage among ileostomists. Br J Nurs. 2009;18:S12–17.
  21. Sier MF, Oostenbroek RJ, Dijkgraaf MGW, et al. Home visits as part of a new care pathway (iAID) to improve quality of care and quality of life in ostomy patients: a cluster-randomized stepped-wedge trial. Colorectal Dis. 2017;19:739-749.
  22. Colombara F, Martinato M, Girardin G, et al. Higher levels of knowledge reduce health care costs in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:615–622.
  23. Glozman JM, Bicheva KG, Fedorova NV. Scale of Quality of Life of Care-Givers (SQLC). J Neurol. 1998;245 Suppl 1:S39-S41.
  24. Lim JW, Zebrack B. Caring for family members with chronic physical illness: A critical review of caregiver literature. Health Qual Life Outcomes. 2004;2:50.
  25. Episodic Disability Network. Brief from the Episodic Disability Network. 2011. Available at: www.parl.gc.ca/Content/HOC/Committee/411/FINA/WebDoc/WD5138047/41.... Accessed July 10, 2015
  26. Israeli E, Graff LA, Clara I, et al. Low prevalence of disability among patients with inflammatory bowel diseases a decade after diagnosis. Clin Gastroenterol Hepatol. 2014;12:1330–1337.e2.
  27. Restall GJ, Simms AM, Walker JR, et al. Understanding Work Experiences of People with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:1688-1697.
  28. Henderson P, Hansen R, Cameron FL, et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis. 2012;18:999–1005.
  29. Jostins L, Ripke S, Weersma RK, et al.; International IBD Genetics Consortium [IIBDGC]. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124.
  30. Lee D, Albenberg L, Compher C, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology. 2015;148:1087–1106.
  31. Tilg H, Moschen AR. Food, immunity, and the microbiome. Gastroenterology. 2015;148:1107–1119.
  32. Hart AR, Luben R, Olsen A, et al. Diet in the aetiology of ulcerative colitis: a European prospective cohort study. Digestion. 2008;77:57–64.
  33. Sigall-Boneh R, Levine A, Lomer M, et al. Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]. J Crohns Colitis. 2017;11:1407-1419.
  34. Gerasimidis K, McGrogan P, Edwards CA. The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. J Hum Nutr Diet 2011;24:313–26.
  35. Brasil Lopes M, Rocha R, Castro Lyra A, et al. Restriction of dairy products; a reality in inflammatory bowel disease patients. Nutr Hosp. 2014;29:575–581.
  36. Verspreet J, Damen B, Broekaert WF, et al. A critical look at prebiotics within the dietary fiber concept. Annu Rev Food Sci Technol. 2016;7:annurev-food-081315-032749.
  37. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954–963.
  38. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47–91.
  39. Roukens AH, Visser LG. Yellow fever vaccine: past, present and future. Expert Opin Biol Ther. 2008;8:1787–1795.
  40. Centre for Evidence Based Medicine, Oxford. Levels of evidence and grades of recommendation. Available at: www.cebm.net/index.aspx?o¼1025. Accessed August 31, 2011.
  41. Davis SC, Robinson BL, Vess J, et al. Primary care management of ulcerative colitis. Nurse Pract. 2017 Dec 4. [Epub ahead of print]
  42. Kornbluth A, Sachar DB. Practice parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–523.
  43. Lim ML, Wallace MR. Infectious diarrhea in history. Infect Dis Clin North Am. 2004;18:261–274.
  44. Francois Joseph Victor Broussais (1772–1838). System of physiological medicine. JAMA. 1969;209:1523.
  45. Wilks S. Morbid appearances in the intestines of Miss Bankes. Lond Med Gaz. 1859;2:264–265
  46. Crohn’s and Colitis Foundation of America. Diagnosing and managing IBD. 2011. www.ccfa.org/assets/pdfs/diagnosing-and-managing-ibd-1.pdf.
  47. Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto Consensus. Gastroenterology. 2015;148(5):1035-1058.e3.
  48. Svartz N. The treatment of 124 cases of ulcerative colitis with salazopyrine and attempts of desensibilization in cases of hypersensitiveness to sulfa. Acta Med Scand. 1948;131:465–472.
  49. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048.
  50. Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust. 1962;49:592–593.
  51. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
  52. Wright AD. Ulcerative colitis complicated by polyarthritis treated by total colectomy. Proc R Soc Med. 1942;35:189–190.
  53. Jostins L, Ripke S,Weersma RK, et al. International IBD Genetics Consortium (IIBDGC). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
  54. Shouval DS, Rufo PA. The Role of Environmental Factors in the Pathogenesis of Inflammatory Bowel Diseases: A Review. JAMA Pediatr. 2017;171:999-1005.
  55. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn’s disease. Gut. 2014;63:776-784.
  56. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology. 2013;145:
  57. Yu YR, Rodriguez JR. Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26:349-355.
  58. Davis SC, Robinson BL, Vess J, et al. Primary care management of ulcerative colitis. Nurse Pract. 2017 Dec 4. [Epub ahead of print]
Logo Janssen | Pharmaceutical Companies of Johnson & Johnson